CME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CME Group Inc is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company has strong market positioning and a recent analyst upgrade, the technical indicators are bearish, and there are no clear proprietary trading signals or recent congressional trading data to support a strong buy decision. Additionally, regulatory challenges and mixed sentiment from analysts suggest caution. Holding the stock or waiting for a clearer entry point may be more prudent.
The MACD is negatively expanding (-0.335), RSI is neutral at 26.36, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 248.802) but far from its pivot (258.119). Overall, the technical indicators suggest a bearish trend.
Keefe Bruyette upgraded CME to Outperform, citing overblown fears about perpetual futures and a strong market position. The company has low retail exposure and strong index licenses in equities products.
CME is suing the CFTC over perpetual futures approval, which could create regulatory uncertainty. Analysts like Erste Group and Barclays have downgraded or lowered price targets, citing concerns about trading volumes and fee momentum. Technical indicators are bearish, and the stock has a historical trend of potential decline in the next month (-10.05%).
No financial data available for the latest quarter, making it difficult to assess growth trends.
Recent upgrades (e.g., Keefe Bruyette to Outperform) highlight attractive risk/reward and an improving volume backdrop. However, some analysts (e.g., Erste Group and Barclays) have downgraded or lowered price targets due to concerns about trading volumes and fee momentum. Price targets range from $239 to $362, with mixed sentiment overall.
